---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-024290"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2023-05-25T23:59:59+00:00"
generated_at: "2026-06-14T14:52:18.002086+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relay reports complete dose escalation data for RLY-4008; 73% ORR in FGFRi-naïve CCA at pivotal dose

## Summary
- Among FGFRi-naïve FGFR2-fusion CCA patients at or above 70mg QD (n=11): 73% ORR, median DoR 11.2 months.
- Patients at lower doses (n=14): 36% ORR; median DoR 5.6 months.
- Safety consistent with prior data: no Grade 4/5 AEs; off-target hyperphosphatemia/diarrhea clinically insignificant.
- Data cut-off Jan 30, 2023; presentation at ASCO on June 4, 2023.
- Pivotal cohort enrollment completion and initial non-CCA expansion data expected in H2 2023.

## SEC filing metadata
- accession: 0000950170-23-024290
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2023-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017023024290/0000950170-23-024290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017023024290/rlay-20230525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-024290
- JSON: https://secwatch.observer/filing/0000950170-23-024290.json
- Plain text: https://secwatch.observer/filing/0000950170-23-024290.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.